March - 2020

MECFA Blog

Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Stenotrophomonas maltophilia is one of the most common emerging multi-drug resistant organisms found in the lungs of people with cystic...

Claire’s Place Foundation Launches COVID-19 Emergency Fund for People with Cystic Fibrosis

Claire’s Place Foundation medical expert recommends all with cystic fibrosis self-quarantine immediately Claire’s Place Foundation, a...

COVID-19: NGO Commends Nana Addo For Suspending Foreign Travels For Gov’t Officials

The Management and Board of Community Focus Foundation Ghana (CFF-GH) has applauded the President of Ghana, H.E Nana Addo Dankwa...

New CRISPR Tool Fixes CFTR Mutations in CF Patients’ Stem Cells, Study Finds

A new variation of the gene-editing technology CRISPR-Cas9 can correct mutations in the CFTR gene — the genetic cause of cystic fibrosis...

New drugs aim to disarm the immune system’s ‘atomic bomb’ cells

Seeking a new treatment for people who have dangerous blockages in their coronary arteries, doctors in London are trying to disarm the...

Inhaled Messenger RNA Treatment Fast-Tracked for Cystic Fibrosis

The Food and Drug Administration has granted Fast Track designation to MRT5005 (Translate Bio), an inhaled messenger RNA (mRNA)...

COVID-19 in Chronic Lung Disease: What You Need to Know

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and novel coronavirus disease (COVID-19) have been of major concern to the...

This new treatment helps 90% of cystic fibrosis patients breathe better

Vertex’s Trikafta was the second-fastest FDA approval in history, and could help some 27,000 patients. In October 2019, Vertex...

CFTR Amplifiers May Be Potent CF Mono or Combo Therapy, Study Says

Amplifiers, a potential new class of therapies that modify CFTR — the protein whose defects cause cystic fibrosis (CF) — do so by...

UK NICE to Announce Decision on Vertex’s Therapy Trikafta in December

The National Institute for Health and Care Excellence (NICE) in the U.K. is currently in the process of evaluating Vertex...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p